We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

128 hedge funds and large institutions have $1.11B invested in Intra-Cellular Therapies Inc. in 2015 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 44 increasing their positions, 31 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

463% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 8

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

93% more capital invested

Capital invested by funds: $576M → $1.11B (+$538M)

42% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 31

41% more funds holding

Funds holding: 91 → 128 (+37)

27% more call options, than puts

Call options by funds: $22.1M | Put options by funds: $17.5M

Holders
128
Holders Change
+37
Holders Change %
+40.66%
% of All Funds
3.57%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.08%
New
45
Increased
44
Reduced
31
Closed
8
Calls
$22.1M
Puts
$17.5M
Net Calls
+$4.68M
Net Calls Change
+$280K

Top Buyers

1
TCM
TimesSquare Capital Management
New York
+$35.9M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$34M
3
State Street
State Street
Massachusetts
+$28.7M
4
RG
Redmile Group
California
+$23.2M
5
BBA
Baker Bros. Advisors
New York
+$16.5M

Top Sellers

1
PC
Pier Capital
Connecticut
-$8.22M
2
WSA
Wall Street Associates
California
-$5M
3
BFA
BlackRock Fund Advisors
California
-$3.42M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.93M
5
TCM
Tekla Capital Management
Massachusetts
-$2.52M
Name Holding Trade Value Shares
Change 		Change in
Stake
CCI
26
Columbus Circle Investors
$9.8M +$7.99M +244,842 New
EAM
27
EverPoint Asset Management
Connecticut
$9.01M -$2.45M -75,000 -25%
Loomis, Sayles & Company
28
Loomis, Sayles & Company
Massachusetts
$8.7M +$6.49M +198,895 +1,087%
WSA
29
Wall Street Associates
California
$8.23M -$5M -153,200 -43%
Allianz Asset Management
30
Allianz Asset Management
Germany
$7.7M +$6.27M +192,238 New
Renaissance Technologies
31
Renaissance Technologies
New York
$7.33M +$5.97M +183,091 New
RSCM
32
Rock Springs Capital Management
Maryland
$7.21M +$5.87M +180,000 New
Geode Capital Management
33
Geode Capital Management
Massachusetts
$6.74M +$109K +3,333 +2%
RPAM
34
Rhenman & Partners Asset Management
Sweden
$6.61M -$1.34M -41,000 -20%
TCM
35
Tekla Capital Management
Massachusetts
$6.01M -$2.52M -77,164 -34%
BIM
36
BlackRock Investment Management
Delaware
$5.83M +$817K +25,037 +21%
Lord, Abbett & Co
37
Lord, Abbett & Co
New Jersey
$5.45M +$4.44M +136,119 New
Bank of New York Mellon
38
Bank of New York Mellon
New York
$5.43M -$515K -15,778 -10%
Invesco
39
Invesco
Georgia
$5.22M +$4.18M +128,064 +5,508%
WRF
40
Waddell & Reed Financial
Kansas
$5.08M +$4.14M +126,800 New
CS
41
Candriam SCA
Luxembourg
$4.65M -$1.82M -55,800 -32%
BlackRock
42
BlackRock
New York
$4.65M +$2.51M +76,900 +197%
WMSA
43
Weiss Multi-Strategy Advisers
New York
$4.57M +$3.07M +94,000 +470%
Deutsche Bank
44
Deutsche Bank
Germany
$4.39M +$3.41M +104,501 +2,004%
SFM
45
Sphera Funds Management
Israel
$4.22M -$737K -22,600 -18%
LCM
46
Laurion Capital Management
New York
$3.83M +$3.12M +95,700 New
EI
47
EAM Investors
California
$3.81M -$1.87M -57,221 -38%
DCM
48
Driehaus Capital Management
Illinois
$3.55M +$2.89M +88,561 New
TCIM
49
TIAA CREF Investment Management
New York
$3.52M -$213K -6,528 -7%
TAM
50
Tocqueville Asset Management
New York
$2.67M +$2.18M +66,775 New
1
2
3 4 5

ITCI Hedge Fund Activity: Q3 2015 in Review

128 of the 3,581 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q3 2015, worth a combined $1.11B — up 93% from $576M a quarter earlier.

Buyers outnumbered sellers: 45 funds opened new ITCI positions and 8 closed out — a net gain of 37 holders — while 44 added to existing stakes and 31 trimmed.

The largest buyer was TimesSquare Capital Management, opening a new position worth an estimated $35.9M. The largest seller was Pier Capital, exiting entirely with an estimated $8.22M sold.

  • 128 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q3 2015, up from 91 in Q2 2015.
  • Funds reported $1.11B of Intra-Cellular Therapies Inc. stock for Q3 2015, up 93% quarter-over-quarter.
  • 45 funds opened new Intra-Cellular Therapies Inc. positions in Q3 2015 and 8 closed out, a net change of +37 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q3 2015 was TimesSquare Capital Management, an estimated $35.9M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q3 2015 was Pier Capital, an estimated $8.22M sold.

Based on aggregated 13F filings for Q3 2015.